Open AccessEFFECT OF LONG‐TERM THERAPY WITH ESTROGEN AND PROGESTERONE ON THE ENDOMETRIUM OF POST‐MENOPASUAL WOMEN
Author(s) -
Varma T. R.
Publication year - 1985
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.3109/00016348509154686
Subject(s) - medicine , dose , endometrium , estrogen , norethisterone , dydrogesterone , norgestrel , norethisterone acetate , endocrinology , estriol , endometrial hyperplasia , population , family planning , research methodology , environmental health
. We studied a group of 398 patients who had been receiving estrogen replacement therapy since 1976. Group I consisted of 138 patients who received Premarin (conjugated equine estrogen, Ayerst) in two different dosages (0.625; 1.25 mg) and progestational agents such as Neogest (Norgestrel, Schering), Duphaston (Dydrogesterone, Duphar) 5 mg and Primolut N (Norethisterone, Schering) 5 mg, for a period ranging between 7 and 21 days. Group II consisted of 106 patients who received Harmogen (Pipera‐zine Oestrone Sulphate, Abbott) in two different dosages (1.5 mg; 2.25 mg) with the above‐mentioned progestational agents for a period ranging between 7 and 21 days. Group III consisted of 154 patients who received Progynova (Oestradiol Valerate, Schering) in two different dosages (1 mg; 2 mg) with the above‐mentioned progestational agents for a period ranging between 7 and 21 days. When increasing dosages of estrogen with progestational agents were added for 7 days, this produced cystic hyperplasia of the en‐dometrium. When the duration of progestational agents was increased to 10 days or more, a more atrophic and secretory endometrium resulted and there was no incidence of cystic hyperplasia.